NASDAQ:SYRE

Spyre Therapeutics (SYRE) Stock Price, News & Analysis

Spyre Therapeutics logo
$98.63 -2.83 (-2.79%)
As of 10:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Spyre Therapeutics Stock (NASDAQ:SYRE)

Advanced

Key Stats

Today's Range
$99.00
▼
$103.50
50-Day Range
$78.63
▼
$109.00
52-Week Range
$23.01
▼
$110.64
Volume
119,890 shs
Average Volume
1.12 million shs
Market Capitalization
$9.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.53
Consensus Rating
Moderate Buy

Company Overview

Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions.

The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.

Spyre was formed in 2023 through a business combination with Aeglea BioTherapeutics, which subsequently adopted the Spyre Therapeutics name. The company is based in the United States and is focused on developing treatments for patients with inflammatory bowel disease.

AI Generated. May Contain Errors.

Spyre Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

SYRE MarketRank™: 
1.85121817684 of 5 stars

Spyre Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 1269th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spyre Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 2 strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Spyre Therapeutics is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Spyre Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Spyre Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Spyre Therapeutics are expected to decrease in the coming year, from ($2.78) to ($3.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spyre Therapeutics is -37.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spyre Therapeutics is -37.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spyre Therapeutics has a P/B Ratio of 10.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    14.51% of the float of Spyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spyre Therapeutics has a short interest ratio ("days to cover") of 12.69, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Spyre Therapeutics has recently decreased by 7.10%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Spyre Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Spyre Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Spyre Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Spyre Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    2 people have searched for SYRE on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,349,518.00 in company stock.

  • Percentage Held by Insiders

    15.69% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Spyre Therapeutics' insider trading history.
Receive SYRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYRE Stock News Headlines

The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
Spyre Therapeutics Announces Grants of Inducement Awards
See More Headlines

SYRE Stock Analysis - Frequently Asked Questions

Spyre Therapeutics' stock was trading at $32.76 at the start of the year. Since then, SYRE stock has increased by 209.7% and is now trading at $101.46.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) released its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.12.

Spyre Therapeutics (SYRE) raised $85 million in an initial public offering (IPO) on Wednesday, April 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share.

Top institutional shareholders of Spyre Therapeutics include State Street Corp (3.72%), Goldman Sachs Group Inc. (1.27%), Assenagon Asset Management S.A. (0.59%) and Marshall Wace LLP (0.57%). Insiders that own company stock include Cameron Turtle, Scott L Burrows, Michael Thomas Henderson, Sheldon Sloan, Jeffrey W Albers, Heidy King-Jones and Fairmount Funds Management Llc.
View institutional ownership trends
.

Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spyre Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), Credo Technology Group (CRDO), Definium Therapeutics (DFTX) and Kratos Defense & Security Solutions (KTOS).

Company Calendar

Last Earnings
11/03/2026
Today
11/19/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Citi Annual Global Healthcare Conference 2026
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SYRE
Previous Symbol
NASDAQ:SYRE
CIK
1636282
Employees
130
Year Founded
2013

Price Target and Rating

High Price Target
$135.00
Low Price Target
$80.00
Potential Upside/Downside
+12.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.74)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$155.20 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-35.97%
Return on Assets
-27.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
27.40
Quick Ratio
27.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.53 per share
Price / Book
10.35

Miscellaneous

Outstanding Shares
94,969,000
Free Float
80,068,000
Market Cap
$9.37 billion
Optionable
Optionable
Beta
3.24
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:SYRE) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners